Products
Streamlined Sample-to-Report Solutions for Next-Generation Non-invasive Prenatal Screening:
Heristar™ Cell-free DNA Sequencing Library Preparation Kit
Use in-depth sequencing data to get a 360-degree view of pregnancies
Heristar provides all-in-one testing kits for the next-generation non-invasive prenatal screening of 80+ severe aneuploidies, microdeletions/duplications and monogenic disorders.
Unprecedented velocity, impeccable reliability
We developed an innovative coordinative allele-aware target-enrichment sequencing technology to detect clinically relevant fetal chromosomal and monogenic variations with 98.5% sensitivity and 99.3% specificity.
Dive Into the New Age of Prenatal Genetic Screening with Heristar
Enhanced and Cost-effective Products
Complete wet and dry lab solutions to expand your testing menu at a lower operation cost and improved test performance
Versatility in Application
Flexible kit configuration tailored for your patients' specific needs
Data Science Acceleration
End-to-end bioinformatics solutions for variant detection and interpretation
Full Client-centric Service
Assistance for rapid and robust new test roll-out process (training for laboratory procedures and reporting, assistance for LDT validation, software upgrades…)
BETTER DECISIONS
BETTER LIFE
Clinical Services
The NIPS2.0 Prenatal cfDNA Screening is a laboratory-developed test utilizing next-generation sequencing and high throughput hybridization-based capture technology. It is designed to evaluate the fetal risk associated with various types of genetic conditions, including single-gene pathogenic variants, microdeletions, and aneuploidies, providing critical information for pregnancy management.
NIPS 2.0 Test Characteristics
-
Ten aneuploidies, 12 microdeletions, and dominant monogenic diseases associated with 56 genes are screened
-
Can be performed as early as nine weeks
-
Fetal sex will be reported
-
Fetal fraction will be reported
-
Trisomy 21, 18, and 13 will be reported for twin pregancies
-
8-10 ml whole blood collected in NIPT-compliant blood tubes
-
Test TAT: 8-10 days
-
98.5% sensitivity and 99.3% specificity on target disorders (validation results published on Nature Medicine, 2024)
Why Use NIPS 2.0
Patients
Patients will receive the most comprehensive non-invasive prenatal screening test which is provided by an accredited clinical laboratory based in the United States. Complimentary genetic counseling will be offered by American board-certified clinical professionals for cases with positive screening results.
Healthcare providers
Healthcare providers can order a single prenatal screening test for their patients, in which aneuplodies, microdeletions, and monogenic disorders are previously analyzed by multiple testing workflows. Complimentary genetic counseling sessions can be provided remotely in English for cases with positive screening results.